Extrapulmonary tuberculosis in HIV-infected patients in rural Tanzania: The prospective Kilombero and Ulanga antiretroviral cohort.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
09
2019
accepted:
15
02
2020
entrez:
5
3
2020
pubmed:
5
3
2020
medline:
19
6
2020
Statut:
epublish
Résumé
In sub-Saharan Africa, diagnosis and management of extrapulmonary tuberculosis (EPTB) in people living with HIV (PLHIV) remains a major challenge. This study aimed to characterize the epidemiology and risk factors for poor outcome of extrapulmonary tuberculosis in people living with HIV (PLHIV) in a rural setting in Tanzania. We included PLHIV >18 years of age enrolled into the Kilombero and Ulanga antiretroviral cohort (KIULARCO) from 2013 to 2017. We assessed the diagnosis of tuberculosis by integrating prospectively collected clinical and microbiological data. We calculated prevalence- and incidence rates and used Cox regression analysis to evaluate the association of risk factors in extrapulmonary tuberculosis (EPTB) with a combined endpoint of lost to follow-up (LTFU) and death. We included 3,129 subjects (64.5% female) with a median age of 38 years (interquartile range [IQR] 31-46) and a median CD4+ cell count of 229/μl (IQR 94-421) at baseline. During the median follow-up of 1.25 years (IQR 0.46-2.85), 574 (18.4%) subjects were diagnosed with tuberculosis, whereof 175 (30.5%) had an extrapulmonary manifestation. Microbiological evidence by Acid-Fast-Bacillus stain (AFB-stain) or Xpert® MTB/RIF was present in 178/483 (36.9%) patients with pulmonary and in 28/175 (16.0%) of patients with extrapulmonary manifestations, respectively. Incidence density rates for pulmonary Tuberculosis (PTB and EPTB were 17.9/1000person-years (py) (95% CI 14.2-22.6) and 5.8/1000 py (95% CI 4.0-8.5), respectively. The combined endpoint of death and LTFU was observed in 1058 (33.8%) patients, most frequently in the subgroup of EPTB (47.2%). Patients with EPTB had a higher rate of the composite outcome of death/LTFU after TB diagnosis than with PTB [HR 1.63, (1.14-2.31); p = 0.006]. The adjusted hazard ratios [HR (95% CI)] for death/LTFU in EPTB patients were significantly increased for patients aged >45 years [HR 1.95, (1.15-3.3); p = 0.013], whereas ART use was protective [HR 0.15, (0.08-0.27); p <0.001]. Extrapulmonary tuberculosis was a frequent manifestation in this cohort of PLHIV. The diagnosis of EPTB in the absence of histopathology and mycobacterial culture remains challenging even with availability of Xpert® MTB/RIF. Patients with EPTB had increased rates of mortality and LTFU despite early recognition of the disease after enrollment.
Sections du résumé
BACKGROUND
In sub-Saharan Africa, diagnosis and management of extrapulmonary tuberculosis (EPTB) in people living with HIV (PLHIV) remains a major challenge. This study aimed to characterize the epidemiology and risk factors for poor outcome of extrapulmonary tuberculosis in people living with HIV (PLHIV) in a rural setting in Tanzania.
METHODS
We included PLHIV >18 years of age enrolled into the Kilombero and Ulanga antiretroviral cohort (KIULARCO) from 2013 to 2017. We assessed the diagnosis of tuberculosis by integrating prospectively collected clinical and microbiological data. We calculated prevalence- and incidence rates and used Cox regression analysis to evaluate the association of risk factors in extrapulmonary tuberculosis (EPTB) with a combined endpoint of lost to follow-up (LTFU) and death.
RESULTS
We included 3,129 subjects (64.5% female) with a median age of 38 years (interquartile range [IQR] 31-46) and a median CD4+ cell count of 229/μl (IQR 94-421) at baseline. During the median follow-up of 1.25 years (IQR 0.46-2.85), 574 (18.4%) subjects were diagnosed with tuberculosis, whereof 175 (30.5%) had an extrapulmonary manifestation. Microbiological evidence by Acid-Fast-Bacillus stain (AFB-stain) or Xpert® MTB/RIF was present in 178/483 (36.9%) patients with pulmonary and in 28/175 (16.0%) of patients with extrapulmonary manifestations, respectively. Incidence density rates for pulmonary Tuberculosis (PTB and EPTB were 17.9/1000person-years (py) (95% CI 14.2-22.6) and 5.8/1000 py (95% CI 4.0-8.5), respectively. The combined endpoint of death and LTFU was observed in 1058 (33.8%) patients, most frequently in the subgroup of EPTB (47.2%). Patients with EPTB had a higher rate of the composite outcome of death/LTFU after TB diagnosis than with PTB [HR 1.63, (1.14-2.31); p = 0.006]. The adjusted hazard ratios [HR (95% CI)] for death/LTFU in EPTB patients were significantly increased for patients aged >45 years [HR 1.95, (1.15-3.3); p = 0.013], whereas ART use was protective [HR 0.15, (0.08-0.27); p <0.001].
CONCLUSIONS
Extrapulmonary tuberculosis was a frequent manifestation in this cohort of PLHIV. The diagnosis of EPTB in the absence of histopathology and mycobacterial culture remains challenging even with availability of Xpert® MTB/RIF. Patients with EPTB had increased rates of mortality and LTFU despite early recognition of the disease after enrollment.
Identifiants
pubmed: 32130279
doi: 10.1371/journal.pone.0229875
pii: PONE-D-19-26934
pmc: PMC7055864
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0229875Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Swiss Med Wkly. 2017 Jul 11;147:w14485
pubmed: 28695551
Nat Rev Microbiol. 2012 Jan 09;10(2):150-6
pubmed: 22230950
Epidemiol Infect. 2017 Sep;145(12):2500-2509
pubmed: 28748775
AIDS. 2015 Sep 24;29(15):1987-2002
pubmed: 26266773
AIDS. 2019 May 1;33(6):1031-1041
pubmed: 30946157
Rev Infect Dis. 1990 Jul-Aug;12(4):583-90
pubmed: 2385765
Sci Rep. 2014 Jul 11;4:5658
pubmed: 25014250
J Clin Diagn Res. 2013 Aug;7(8):1644-6
pubmed: 24086863
PLoS One. 2016 Mar 07;11(3):e0150646
pubmed: 26950547
HIV AIDS (Auckl). 2018 Nov 05;10:225-237
pubmed: 30464643
PLoS One. 2013 May 17;8(5):e63541
pubmed: 23691062
Cochrane Database Syst Rev. 2018 Aug 27;8:CD012768
pubmed: 30148542
PLoS One. 2019 Jan 9;14(1):e0209650
pubmed: 30625188
N Engl J Med. 2010 Sep 9;363(11):1005-15
pubmed: 20825313
Respir Med. 2008 Aug;102(8):1159-64
pubmed: 18573650
Emerg Microbes Infect. 2018 Jun 6;7(1):102
pubmed: 29872046
J Int AIDS Soc. 2019 Apr;22(4):e25240
pubmed: 31038836
Indian J Med Res. 2004 Oct;120(4):316-53
pubmed: 15520485
J Clin Microbiol. 2011 Dec;49(12):4138-41
pubmed: 21956978
Am J Med. 1974 Apr;56(4):494-505
pubmed: 4206484
Iran J Public Health. 2016 Mar;45(3):305-13
pubmed: 27141492
Eur Respir J. 2012 Aug;40(2):442-7
pubmed: 22241741
Int J Clin Exp Med. 2014 Oct 15;7(10):3126-35
pubmed: 25419343
Open Forum Infect Dis. 2019 Apr 25;6(4):ofz154
pubmed: 31041350
J Int AIDS Soc. 2019 Sep;22(9):e25392
pubmed: 31507083
PLoS One. 2015 Apr 21;10(4):e0123275
pubmed: 25897491
mBio. 2017 Aug 29;8(4):
pubmed: 28851844
J Int AIDS Soc. 2018 Feb;21(2):
pubmed: 29479867
Am J Respir Crit Care Med. 1998 Jul;158(1):157-61
pubmed: 9655723
Cochrane Database Syst Rev. 2016 May 10;(5):CD011420
pubmed: 27163343
Infect Dis Poverty. 2018 Mar 24;7(1):24
pubmed: 29580279
Lancet Infect Dis. 2014 Jun;14(6):527-32
pubmed: 24438820
Clin Infect Dis. 2018 Nov 13;67(11):1643-1652
pubmed: 29889240
PLoS One. 2017 Jul 18;12(7):e0180983
pubmed: 28719610
BMC Med. 2014 Jun 18;12:101
pubmed: 24942470
Pan Afr Med J. 2017 Mar 03;26:126
pubmed: 28533849
Trop Geogr Med. 1991 Oct;43(4):375-8
pubmed: 1812603
Am J Trop Med Hyg. 2018 Jan;98(1):266-273
pubmed: 29141727
J Clin Microbiol. 2010 Jul;48(7):2495-501
pubmed: 20504986
Lancet Glob Health. 2019 Feb;7(2):e191-e199
pubmed: 30683238
Am J Med. 1990 Sep;89(3):291-6
pubmed: 2393033
BMC Public Health. 2014 Apr 07;14:319
pubmed: 24708793
PLoS One. 2015 Sep 29;10(9):e0138413
pubmed: 26418678
PLoS One. 2014 Apr 22;9(4):e95603
pubmed: 24755603